Working… Menu

Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00346684
Recruitment Status : Completed
First Posted : June 30, 2006
Last Update Posted : August 12, 2008
Information provided by:
University of Cologne

Brief Summary:
First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab

Condition or disease Intervention/treatment Phase
Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD) Drug: Rituximab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Rituximab in Primary LPHD (RIPL) - First Line Therapy for Patients With Lymphocyte Predominant Hodgkin´s Disease (LPHD) in Clinical Stage IA Using the Monoclonal Anti-CD20 Antibody Rituximab.
Study Start Date : July 2006
Actual Primary Completion Date : November 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hodgkin Disease
Drug Information available for: Rituximab

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • lymphocyte predominant Hodgkin´s lymphoma (histologically proven)
  • clinical stage IA (without risk factors: large mediastinal mass, extranodal involvement, ESR > 50mm/h)
  • age 18 - 75
  • WHO performance status 0-3
  • normal organ function
  • written informed consent

Exclusion Criteria:

  • classical Hodgkin´s lymphoma
  • composite lymphoma
  • leucocytes < 3000/µl
  • thrombocytes < 100.000/µl

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00346684

Layout table for location information
University of Cologne
Cologne, Germany, 50931
Sponsors and Collaborators
University of Cologne
Layout table for investigator information
Principal Investigator: Andreas Engert Universitiy of Cologne

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00346684     History of Changes
Other Study ID Numbers: RIPL
First Posted: June 30, 2006    Key Record Dates
Last Update Posted: August 12, 2008
Last Verified: August 2008
Keywords provided by University of Cologne:
Additional relevant MeSH terms:
Layout table for MeSH terms
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents